Compliance set to be big challenge for EU industry
This article was originally published in SRA
Executive Summary
Life sciences companies in Europe will find regulatory compliance "a major challenge" over the next few years as the UK Bribery Act, and other measures, comes in to force, shows a survey from Cegedim Relationship Management1. Firms will have to revaluate how sales reps – "the face of industry" – are used and get to grips with operational compliance.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.